Adrenal hypoplasia congenita (AHC) is a rare X‐linked condition marked by an underdeveloped adrenal cortex and a spectrum of endocrine anomalies, most notably primary adrenal insufficiency and ...

Please provide your email address to receive an email when new articles are posted on . New therapies are needed to better address the comorbidities associated with congenital adrenal hyperplasia, ...

Crenessity is expected to be available commercially in approximately 1 week through PANTHERx Rare, a specialty pharmacy. The Food and Drug Administration (FDA) has approved Crenessity TM (crinecerfont ...

People with classic congenital adrenal hyperplasia (CAH) often experience fertility issues, but hormone-balancing treatment can help. This rare genetic disorder is most often caused by a ...

Crinecerfont was approved for use in combination with glucocorticoids in patients ages 4 years and older with the rare genetic condition that impacts the adrenal glands. Acting as a potent and ...

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH) due to ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

Classic congenital adrenal hyperplasia (CAH) is a condition that is passed down in families. It is a serious condition that can be deadly if not treated. One of the treatments for classic CAH is ...